Literature DB >> 18673194

Ligands and therapeutic perspectives of adenosine A(2A) receptors.

C Diniz1, F Borges, L Santana, E Uriarte, J M A Oliveira, J Gonçalves, P Fresco.   

Abstract

Adenosine A(2A) receptors are members of the G protein-coupled receptor family and mediate multiple physiological effects of adenosine, both at the central nervous system (CNS) and at peripheral tissues, by activating several pathways or interacting with other receptors or proteins. Increasing evidence relate A(2A) receptors with pharmacological stress testing, neurodegenerative disorders (such as Parkinson's disease) and inflammation, renewing the interest in these receptors, increasingly viewed as promising therapeutic targets. Series of agonists and antagonists have been developed by medicinal chemistry artwork either by structure activity relationship (SAR) or quantitative structure activity relationship (QSAR) studies. These studies have allowed identification of the structural and electrostatic requirements for high affinity A(2A) receptor binding and, therefore, contributing to the rational design of A(2A) receptor ligands. Additional rational chemical modifications of the existing A(2A) receptor ligands may further improve their affinity/selectivity. The purpose of this review is to analize and summarize aspects related to the medicinal chemistry of A(2A) receptor ligands, their present and potencial therapeutic applications by exploring the molecular structure and physiological and pathophysiological roles of A(2A) receptors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18673194     DOI: 10.2174/138161208784746842

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  6 in total

1.  Novel Alexa Fluor-488 labeled antagonist of the A(2A) adenosine receptor: Application to a fluorescence polarization-based receptor binding assay.

Authors:  Miklós Kecskés; T Santhosh Kumar; Lena Yoo; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2010-05-11       Impact factor: 5.858

2.  Latest QSAR study of adenosine Α₂Β receptor affinity of xanthines and deazaxanthines.

Authors:  Alfonso Pérez-Garrido; Virginia Rivero-Buceta; Gaspar Cano; Sanjay Kumar; Horacio Pérez-Sánchez; Marta Teijeira Bautista
Journal:  Mol Divers       Date:  2015-07-10       Impact factor: 2.943

3.  Intrathecal injection of adenosine 2A receptor agonists reversed neuropathic allodynia through protein kinase (PK)A/PKC signaling.

Authors:  Lisa C Loram; Frederick R Taylor; Keith A Strand; Jacqueline A Harrison; Rachael Rzasalynn; Paige Sholar; Jayson Rieger; Steven F Maier; Linda R Watkins
Journal:  Brain Behav Immun       Date:  2013-06-28       Impact factor: 7.217

4.  Adenosine inhibits chemotaxis and induces hepatocyte-specific genes in bone marrow mesenchymal stem cells.

Authors:  Mehdi Mohamadnejad; Muhammad A Sohail; Azuma Watanabe; Diane S Krause; E Scott Swenson; Wajahat Z Mehal
Journal:  Hepatology       Date:  2010-03       Impact factor: 17.425

Review 5.  The Adenosinergic System as a Therapeutic Target in the Vasculature: New Ligands and Challenges.

Authors:  Joana Beatriz Sousa; Carmen Diniz
Journal:  Molecules       Date:  2017-05-06       Impact factor: 4.411

Review 6.  Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.

Authors:  Chrisna Matthee; Gisella Terre'Blanche; Lesetja J Legoabe; Helena D Janse van Rensburg
Journal:  Mol Divers       Date:  2021-06-27       Impact factor: 3.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.